Wolfe Research analyst Alexandria Hammond initiates coverage on $AbbVie (ABBV.US)$ with a buy rating, and sets the target price at $205.
According to TipRanks data, the analyst has a success rate of 25.0% and a total average return of -15.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $AbbVie (ABBV.US)$'s main analysts recently are as follows:
The recent negative update on emraclidine Phase 2 was unexpected and has prompted a removal of emraclidine from projections, along with an increase in Cobenfy estimates for a competing company. Consequently, this has resulted in an estimated 7% rise in total revenue for the year 2033. Ultimately, this development does not alter the projected revenue or EPS growth trajectory for the associated stocks.
Recently, pivotal Phase 2 trials for AbbVie's emraclidine did not meet the mark in demonstrating a significant change from the baseline in the Positive and Negative Symptom Scale total score in studies aimed at treating schizophrenia. This drug was considered a central piece in AbbVie's major acquisition and was anticipated to bring in significant sales towards the end of the decade, competing with existing treatments. As a consequence, projections for emraclidine have been removed from future financial models.
The recent outcomes from the EMPOWER 1 and 2 Emraclidine Phase 2 studies in Schizophrenia, which showed that placebo outperformed both active arms in both trials, indicate that the primary value proposition from the $8.7B acquisition is now defunct.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
沃爾夫研究分析師Alexandria Hammond首次給予$艾伯維公司 (ABBV.US)$買入評級，目標價205美元。
根據TipRanks數據顯示，該分析師近一年總勝率為25.0%，總平均回報率為-15.3%。
此外，綜合報道，$艾伯維公司 (ABBV.US)$近期主要分析師觀點如下：
對emraclidine第2階段最近的負面更新令人意外，促使將emraclidine從預測中移除，同時提高了對一家競爭公司Cobenfy的估計。因此，這導致了2033年總營業收入預計上升了7%。最終，這一發展並不會改變相關股票的預期營收或每股收益增長軌跡。
最近，AbbVie的emraclidine關鍵第2階段試驗未能在治療精神分裂症的研究中表現出顯著改變，與基線相比沒有達到標準。這種藥物被視爲AbbVie重要收購的核心部分，預計將在本十年末爲公司帶來重要銷售額，與現有治療方法競爭。因此，emraclidine的預測已從未來財務模型中移除。
最近在精神分裂症的EMPOWER 1和2階段2研究中的emraclidine最新結果表明，安慰劑在兩項試驗中均優於兩個用藥組，顯示這$87億收購的主要價值主張目前已失效。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
